drugset / Trial / NCT04109456
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Timeline
- Start
- 2020-03-16
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | — |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Ifebemtinib | Small molecule | 50 mg | Oral |
| Subject | Ifebemtinib | Small molecule | 100 mg | Oral |